Liječnički vjesnik (Jan 2023)

USE OF IMMUNOTHERAPY IN THE TREATMENT OF A PATIENT WITH TWO SIMULTANEOUS METASTATIC DISEASES

  • Matej Penava,
  • Anđelo Kurtin,
  • Katarina Čular,
  • Tajana Silovski

DOI
https://doi.org/10.26800/LV-145-supl2-CR80
Journal volume & issue
Vol. 145, no. Supp 2
pp. 86 – 86

Abstract

Read online

Immunotherapy is an evolving and promising cancer treatment proven to significantly prolong survival in a multitude of oncological diseases. Nivolumab, a monoclonal antibody to the PD-1 receptor, is an immunotherapy used in the treatment of several cancers, including melanoma and renal cell carcinoma (RCC).

Keywords